48. 原発性抗リン脂質抗体症候群 Disease details / Clinical trials / Drug dev / DR info /

臨床試験数 : 9 / 薬物数 : 8 - (DrugBank : 6) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 59

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
Belimumab+SOC
   Ruijin Hospital
      2024   Phase 2   NCT06747312   China
Blood withdrawal
   Centre Hospitalier Universitaire, Amiens
      2023   -   NCT06373926   France
Daratumumab
   National Institute of Allergy and Infectious Diseases (NIAID)
      2023   Phase 1/Phase 2   NCT05671757   United States
EPA and DHA supplementation
   University of Sao Paulo
      2014   -   NCT01956188   Brazil
Hydroxychloroquine
   National and Kapodistrian University of Athens
      2013   -   NCT04153201   Greece
   University Hospital, Angers
      2018   Phase 3   NCT03540810   France
Sirolimus
   Peking University People's Hospital
      2024   Phase 2   NCT06504420   -
Telitacicept
   Peking Union Medical College Hospital
      2021   Phase 2   NCT05078710   China
Telitacicept+SOC
   Ruijin Hospital
      2023   Phase 2   NCT06315530   China